Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
LONDON, Aug. 31, 2017 -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive Officer, will present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017 at 9:05 AM ET in New York. Mr. Sterritt will give a corporate overview, review the Company’s late-stage and commercial product portfolio, and provide an update on upcoming milestones, including key clinical trial readouts and potential subsequent regulatory submission.
An audio webcast of the presentation will be available in the events section of the Company’s website, or by clicking here. A replay will be available for a limited time following the presentation.
About Shield Therapeutics
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals, which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.
| For further information please contact: | |||
| Shield Therapeutics plc | +44 (0) 207 186 8500 | ||
| Joanne Estell, Chief Financial Officer | |||
| Karl Keegan, Corporate Development Director | |||
| Nominated Adviser and Joint Broker | +44 (0)20 3100 2222 | ||
| Liberum Capital Limited | |||
| Christopher Britton | |||
| Steve Pearce | |||
| Jonathan Wilkes-Green | |||
| Joint Broker | +44 (0)20 7418 8900 | ||
| Peel Hunt LLP | |||
| James Steel | |||
| Alastair Rae | |||
| Oliver Jackson | |||
| Financial PR Adviser | +44 (0)203 709 5700 | ||
| Consilium Strategic Communications | |||
| Mary-Jane Elliott/Matthew Neal | |||
| [email protected] | |||
| U.S Investor Relations | + 1 (212)-599-1265 | ||
| Lazar Partners Ltd. | |||
| Matthew Ventimiglia | |||
| [email protected] | |||
